$0.3728
-0.01-3.19%
At close: -
$0.3675
-0.00530-1.42%
After Hours: 4:46 PM EDT
Comments
Loading...
Acurx Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:ACXP | Benzinga
Acurx Pharmaceuticals Inc has a consensus price target of $13 based on the ratings of 2 analysts. The high is $14 issued by Alliance Global Partners on October 20, 2022. The low is $12 issued by HC Wainwright & Co. on March 19, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on March 19, 2025, January 13, 2025, and January 10, 2025, respectively. With an average price target of $12 between HC Wainwright & Co., there's an implied 3165.31% upside for Acurx Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Alliance Global Partners
1calculated from analyst ratings
Analyst Ratings for Acurx Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/19/2025 | Buy Now | 3165.31% | HC Wainwright & Co. | Ed Arce56% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 01/13/2025 | Buy Now | 3165.31% | HC Wainwright & Co. | Ed Arce56% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 01/10/2025 | Buy Now | 3165.31% | HC Wainwright & Co. | Ed Arce56% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 12/10/2024 | Buy Now | 3165.31% | HC Wainwright & Co. | Ed Arce56% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | 3165.31% | HC Wainwright & Co. | Ed Arce56% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | 3165.31% | HC Wainwright & Co. | Ed Arce56% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | 3165.31% | HC Wainwright & Co. | Ed Arce56% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 03/19/2024 | Buy Now | 3165.31% | HC Wainwright & Co. | Ed Arce56% | $14 → $12 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 3709.52% | HC Wainwright & Co. | Ed Arce56% | $14 → $14 | Reiterates | Buy → Buy | Get Alert |
| 12/15/2023 | Buy Now | 3709.52% | HC Wainwright & Co. | Ed Arce56% | $13 → $14 | Maintains | Buy | Get Alert |
| 11/15/2023 | Buy Now | 3437.41% | HC Wainwright & Co. | Ed Arce56% | → $13 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | 3437.41% | HC Wainwright & Co. | Ed Arce56% | → $13 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | Buy Now | 3437.41% | HC Wainwright & Co. | Ed Arce56% | $14 → $13 | Maintains | Buy | Get Alert |
| 05/15/2023 | Buy Now | 3709.52% | HC Wainwright & Co. | Ed Arce56% | → $14 | Reiterates | Buy → Buy | Get Alert |
| 04/11/2023 | Buy Now | 3709.52% | HC Wainwright & Co. | Ed Arce56% | → $14 | Reiterates | → Buy | Get Alert |
| 03/17/2023 | Buy Now | 3709.52% | HC Wainwright & Co. | Ed Arce56% | → $14 | Reiterates | → Buy | Get Alert |
| 12/19/2022 | Buy Now | 3709.52% | HC Wainwright & Co. | Ed Arce56% | → $14 | Initiates | → Buy | Get Alert |
| 10/20/2022 | Buy Now | 3709.52% | Alliance Global Partners | James Molloy30% | → $14 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Acurx Pharmaceuticals (ACXP) stock?
The latest price target for Acurx Pharmaceuticals (NASDAQ:ACXP) was reported by HC Wainwright & Co. on March 19, 2025. The analyst firm set a price target for $12.00 expecting ACXP to rise to within 12 months (a possible 3165.31% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Acurx Pharmaceuticals (ACXP)?
The latest analyst rating for Acurx Pharmaceuticals (NASDAQ:ACXP) was provided by HC Wainwright & Co., and Acurx Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Acurx Pharmaceuticals (ACXP)?
There is no last upgrade for Acurx Pharmaceuticals
When was the last downgrade for Acurx Pharmaceuticals (ACXP)?
There is no last downgrade for Acurx Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Acurx Pharmaceuticals (ACXP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acurx Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acurx Pharmaceuticals was filed on March 19, 2025 so you should expect the next rating to be made available sometime around March 19, 2026.
Is the Analyst Rating Acurx Pharmaceuticals (ACXP) correct?
While ratings are subjective and will change, the latest Acurx Pharmaceuticals (ACXP) rating was a reiterated with a price target of $12.00 to $12.00. The current price Acurx Pharmaceuticals (ACXP) is trading at is $0.37, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
